<DOC>
	<DOCNO>NCT01557322</DOCNO>
	<brief_summary>1 . To assess baseline ( i.e . RA therapy initiation ) characteristic real-world set across two moderate RA cohort : Test Group patient newly expose etanercept ( Enbrel ) therapy Control Group patient similar disease characteristic newly expose , non-biologic therapy . 2 . To assess change time ( baseline recent follow-up ) characteristic describe baseline 2 British Society Rheumatology Biologics Register ( BSRBR ) cohort ( i.e . moderate RA patient treat Disease modify anti-rheumatic drug ( DMARDs ) alone versus moderate RA patient treat Enbrel ) .</brief_summary>
	<brief_title>Characterize Patients With Moderately Active Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description>Retrospective database analysis</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>The Test Group patient rheumatoid arthritis , newly start therapy etanercept ( Enbrel ) . Inclusion criterion expose cohort subject : Patients age 18 year time diagnosis ; Patients BSRBR moderate RA define DAS28 ( &gt; 3.2 ≤5.1 ) ; Patients give informed consent long term followup access medical record ; Patients initiate ( i.e . leats one treatment ) treatment etanercept ( Enbrel ) RA . The Control Group : Patients age 18 year time diagnosis ; Patients BSRBR moderate RA define DAS28 ( &gt; 3.2 ≤5.1 ) ; Patients give informed consent long term followup access medical record ; Patients receive least one traditional DMARD never prescribe biologic agent ; Per BSRBR registry since data retropsectively analyze</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>